A simple drape and a treatment bundle cut severe childbirth bleeding by 60%

A childbirth-bleeding intervention built from cheap, familiar parts — a calibrated drape to measure blood loss objectively, plus a bundle of first-response treatments delivered together — cut the rate of severe postpartum haemorrhage, surgery for bleeding, or death from bleeding from 4.3% to 1.6% in a large trial across four African countries [s1]. That is a 60% relative reduction in the primary outcome (risk ratio 0.40; 95% CI, 0.32 to 0.50) [s1], and it matters because severe bleeding after childbirth is the leading cause of maternal death worldwide [s2].

The World Health Organization estimates that severe bleeding, mostly after childbirth, is among the complications accounting for around 75% of maternal deaths, and that over 700 women died every day in 2023 from preventable causes related to pregnancy and childbirth — roughly one death every two minutes [s2]. The problem is rarely a lack of treatments. It is that bleeding is detected late, by visual estimation that undercounts blood loss, and that the treatments which exist are given piecemeal. The global maternal death rate fell by about 40% between 2000 and 2023, but just over 90% of maternal deaths still occur in low- and lower-middle-income countries [s2] — the settings where tools to detect and treat haemorrhage promptly are least reliably in place.

What the trial did

The E-MOTIVE trial was an international, cluster-randomised study in women having a vaginal delivery [s1]. It enrolled 80 secondary-level hospitals across Kenya, Nigeria, South Africa and Tanzania, covering 210,132 vaginal births, and randomised the hospitals to the intervention or to usual care [s1].

The intervention had two components. First, a calibrated blood-collection drape for early, objective detection of haemorrhage — a V-shaped plastic sheet with marked volume graduations, replacing the guesswork of visual estimation. Second, a bundle of first-response treatments delivered as a single protocol when bleeding was detected: uterine massage, oxytocic drugs, tranexamic acid, intravenous fluids, examination, and escalation — supported by an implementation strategy to get staff to use it [s1].

The primary outcome was a composite of severe postpartum haemorrhage (blood loss of 1,000 mL or more), laparotomy for bleeding, or maternal death from bleeding [s1].

What it found

The primary outcome occurred in 1.6% of women in the intervention group against 4.3% in the usual-care group — risk ratio 0.40 (95% CI, 0.32 to 0.50; P<0.001) [s1].

The two process measures explain how. Haemorrhage was detected in 93.1% of women in the intervention hospitals versus 51.1% under usual care (rate ratio 1.58; 95% CI, 1.41 to 1.76), and the treatment bundle was actually used in 91.2% of cases versus 19.4% (rate ratio 4.94; 95% CI, 3.88 to 6.28) [s1]. In other words, usual care missed roughly half of the haemorrhages and delivered the full bundle in fewer than one in five — and simply closing those gaps is most of what the trial achieved.

What the trial does and does not establish

The effect is large, the trial is large, and the mechanism is transparent: measure bleeding objectively, then treat it promptly and completely. That is a strong combination, and it is the kind of result that changes practice rather than merely adding to a literature.

The limits are equally concrete. The trial was conducted in secondary-level hospitals in four countries and in women having vaginal deliveries; it does not speak to caesarean births, home or primary-care deliveries, or to settings with different baseline care. The primary outcome was a composite dominated by severe bleeding and surgery; the trial was not powered to show, on its own, a reduction in maternal deaths, which are rarer events. And a bundle tested as a package cannot tell you how much each part — the drape, each drug, the implementation push — contributed.

Crucially, the intervention is built from tools that already exist and are inexpensive, which is what makes the detection-and-bundle approach plausible to scale. The trial was funded by the Bill and Melinda Gates Foundation [s1].

What to watch

Whether the approach holds up outside trial conditions and in caesarean deliveries; how fast the calibrated drape and bundle are adopted into national guidelines and supply chains; and whether, at scale and over time, the large drop in severe bleeding translates into fewer maternal deaths. For the scale of the problem that is not moving, see our coverage of Brazil's stalled progress on childbirth-haemorrhage deaths.

This article describes trial results. It is not medical advice.

Sources

1. Randomized Trial of Early Detection and Treatment of Postpartum Hemorrhage — New England Journal of Medicine, 9 May 2023
2. Maternal mortality — World Health Organization, 7 April 2025